Merck & Co., Inc. Stock Forecast, Price & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have increased by 4.6% and is now trading at $82.93.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings data on Friday, July, 31st. The company reported $1.37 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.14 by $0.23. The company earned $10.87 billion during the quarter, compared to the consensus estimate of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The firm's revenue for the quarter was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.30 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. declared a quarterly dividend on Wednesday, July 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a dividend yield of 2.94%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. declared that its board has initiated a stock repurchase plan on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 5.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

Merck & Co., Inc. updated its FY20 earnings guidance on Friday, July, 31st. The company provided EPS guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

13 brokers have issued 1 year price objectives for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.54 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

Media stories about MRK stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 10,970,000 shares, a decrease of 9.4% from the August 31st total of 12,110,000 shares. Based on an average daily trading volume, of 7,950,000 shares, the short-interest ratio is currently 1.4 days. Currently, 0.4% of the company's shares are short sold.
View Merck & Co., Inc.'s Short Interest.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.41%), BlackRock Inc. (7.81%), Bank of New York Mellon Corp (1.25%), Nordea Investment Management AB (0.73%), FMR LLC (0.51%) and Sumitomo Mitsui Trust Holdings Inc. (0.50%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of New York Mellon Corp, Marshall Wace North America L.P., Toronto Dominion Bank, Bank of Nova Scotia, Thornburg Investment Management Inc., CIBC Private Wealth Group LLC, and Victory Capital Management Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Sanat Chattopadhyay, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Point72 Asset Management L.P., Sarasin & Partners LLP, Epoch Investment Partners Inc., Ceredex Value Advisors LLC, BlackRock Inc., TD Asset Management Inc., and Sumitomo Mitsui Trust Holdings Inc..
View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $82.93.

Merck & Co., Inc. has a market capitalization of $209.75 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]